Skip to main content
. 2022 Feb 2;7:13. doi: 10.1038/s41536-022-00208-9

Fig. 5. Local and systemic administration of MBV decrease the ratio of splenic pro-inflammatory M1-like macrophages to anti-inflammatory M2-like macrophages and regulates a myeloid population shift driven by CD43hi/His48lo/CD206+ circulating monocytes.

Fig. 5

a i.p. MTX, p.a. MBV, and i.v. MBV decrease the ratio of splenic pro-inflammatory, M1-like macrophages (CD68+/CD86+/CD206−) to anti-inflammatory, M2-like macrophages (CD68+/CD86−/CD206+) compared to Pristane + PBS (p < 0.05). b UMAP dimensional reduction of the entire splenic myeloid compartment revealed an M2-predominant cluster as outlined in rectangular outline that is unique to MBV treatment. c The M2-predominant cluster unique to MBV treatment is driven by immunoregulatory, CD43hi/His48lo/CD206+ circulating monocytes in the spleen. All values in panels a represent mean ± s.e.m. (n = 4). UMAP plots in b and c represent concatenated values of four biological replicates.